Leukemia Research
Volume 27, Issue 9 , Pages 869-870 , September 2003

Incidence and prognostic significance of C-MPL expression in acute myeloid leukemia

  • Sivatharsini Chelvatheebam

      Affiliations

    • Department of Haematology, University College London, 98 Chenies Mews, London WC1E 6HX, UK
    • ,
  • Stephen E. Langabeer

      Affiliations

    • Department of Haematology, University College London, 98 Chenies Mews, London WC1E 6HX, UK
    • Corresponding Author InformationCorresponding author. Present address: Leukaemia Research Fund Centre, Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, UK. Tel.: +44-20-7153-5551; fax: +44-20-7352-0266.
    • ,
  • Robert K. Hills

      Affiliations

    • Birmingham Clinical Trials Unit, University of Birmingham, Park Grange, 1 Somerset Road, Edgbaston, Birmingham B15 2RR, UK
    • ,
  • Pamela Greenwell

      Affiliations

    • School of Biosciences, University of Westminster, 115 New Cavendish Street, London W1W 6UW, UK
    • ,
  • David C. Linch

      Affiliations

    • Department of Haematology, University College London, 98 Chenies Mews, London WC1E 6HX, UK

Received 7 November 2002

References 

  1. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al.  The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. Blood. 1998;92:2322–2333
  2. Wheatley K, Burnett AK, Goldstone AH, Gray RG, Hann IM, Harrison CJ, et al.  A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. Br. J. Haematol. 1999;107:69–79
  3. Wetzler M, Baer MR, Bernstein SH, Blumenson L, Stewart C, Barcos M, et al.  Expression of c-mpl mRNA, the receptor for thrombopoietin, in acute myeloid leukemia blasts identifies a group of patients with poor response to intensive chemotherapy. J. Clin. Oncol. 1997;15:2262–2268
  4. Albitar M, Manshouri T, Kantarjian H, Keating M, Estrov Z, Faber J, et al.  Correlation between lower c-mpl protein expression and favorable cytogenetic groups in acute myeloid leukemia. Leuk. Res. 1999;23:63–69
  5. Schroder JK, Kolkenbrock S, Tins J, Kasimir-Bauer S, Seeber S, Schutte J. Analysis of thrombopoietin receptor (c-mpl) mRNA expression in de novo acute myeloid leukemia. Leuk. Res. 2000;24:401–409
  6. http://leuktrials.uwcm.ac.uk.
  7. Kaban K, Kantarjian H, Talpaz M, O’Brien S, Cortes J, Giles FJ, et al.  Expression of thrombopoietin and its receptor (c-mpl) in chronic myelogenous leukemia: correlation with disease progression and response to therapy. Cancer. 2000;88:570–576
  8. Duensing S, Duensing A, Meran JG, Kreft A, Busche G, Ganser A, et al.  Molecular detection of c-mpl thrombopoietin receptor gene expression in chronic myeloproliferative disorders. Mol. Pathol. 1999;52:146–150
  9. Yoon SY, Li CY, Tefferi A. Megakaryocyte c-Mpl expression in chronic myeloproliferative disorders and the myelodysplastic syndrome: immunoperoxidase staining patterns and clinical correlates. Eur. J. Haematol. 2000;65:170–174

PII: S0145-2126(03)00016-X

doi: 10.1016/S0145-2126(03)00016-X

Leukemia Research
Volume 27, Issue 9 , Pages 869-870 , September 2003

Article Tools